Daiichi Sankyo collaborates with BostonGene on AI-driven biomarker and ADC development
Daiichi Sankyo is collaborating with BostonGene to integrate AI-driven translational intelligence into an antibody drug conjugate development programme. The work is aimed at biomarker discovery, response prediction, patient selection and trial design across its cancer pipeline.
Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with BostonGene to integrate AI-driven translational intelligence into the core of an antibody drug conjugate development programme. The collaboration is aimed at advancing biomarker discovery and response prediction across its cancer pipeline and delivering decision-ready insights that directly inform patient selection strategies, development prioritisation and translational positioning.
US-based BostonGene, the developer of the leading AI foundation model for tumour and immune biology, announced the strategic collaboration with the Japanese pharmaceutical firm. The programme is intended to move beyond standard exploratory biomarker analysis.
By generating digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles, BostonGene identifies the precise biological signatures and efficacy-associated mechanisms that distinguish responders from non-responders. This deep molecular mapping will enable the collaboration to define unique molecular subgroups by benchmarking the investigational medicine relative to approved treatments and existing standards of care.
The analyses will also help enable clear asset differentiation by identifying unique therapeutic profiles and biological advantages. The platform provides actionable insights into resistance pathways and the tumor microenvironment necessary to optimise future trial design and clinical positioning.